CA-HOTWIRE
30.9.2021 15:02:25 CEST | Business Wire | Press release
Hotwire, the global tech communications consultancy, is welcoming new leaders as the company continues further expansion of its capabilities and adds new, innovative brands to the client roster.
Hotwire is building on its strategic acquisition of McDonald Butler Associates to unlock new possibilities of growth and present clients with a more robust communications offering and access to new skills and services. This new level of communication has been designed to build brand reputation, strengthen stakeholder relationships and deliver revenue growth, igniting the entire marketing ecosystem and supporting CMOs in growing their businesses.
“Technology and innovation leaders are continuing to manage complexity and are seeking out solutions to support,” said Heather Kernahan, global CEO of Hotwire. “This year we took steps to narrow the gaps that exist between marketing and sales with new integrated offerings and strengthened our relationships with clients as they navigated major shifts in their business. We’re also working with some amazing new brands and deepening our expertise and leadership across key areas of the business.”
New Leaders Support Rapid Growth
Hotwire continues to add senior leaders in strategy, planning, digital and client consulting to its teams across the world. This past quarter key hires have been made in Germany, the U.K., and the U.S.
In Germany, Martin Opercan joined Hotwire as a Senior Director, Strategic Growth and will be responsible for client strategy and planning. Martin brings over 20 years of experience in marketing, communications and business development and most recently oversaw the Munich office for diffferent.
Rebecca Rhodes and Anastasia Pavolva recently joined the Hotwire U.K. team. Rebecca is Head of Planning and before joining Hotwire, ran her own consultancy, SuperHuman and also previously was Global Chief Creative Officer at Golin. Anastasia is a Strategy Director with experience working in global agencies such as Ogilvy and in brand management at Procter & Gamble.
In the U.S., two new Senior Vice Presidents will join the leadership and client services team. Andrea Holland has worked in tech comms across large global brands including Intuit, PayPal and LegalZoom as well as early stage B2C tech startups. Andrea is a PR instructor and author for LinkedIn Learning and most recently ran her own consultancy, DialedPR. She also founded the nation's #1 jobs site for PR professionals looking for remote work, RemotePRJobs . Jessica Heagerty comes to Hotwire from Dell Technologies where she held roles in Analyst Relations and Field Marketing. Jessica started her career working for global brands in leading communications agencies.
Tech Innovators Choose Hotwire to Ignite New Opportunities
As Hotwire continues to provide a new level of communication expertise helping companies build brand reputation, strengthen stakeholder relationships and deliver revenue growth, it’s igniting the entire marketing ecosystem and supporting ambitious companies in growing their businesses.
New clients include fast growing and global innovators who selected Hotwire for its technology and innovation expertise and consultancy approach. Most recently, Hotwire signed on Aircall, BAM Karaoke, Bright Machines, Cobrainer, QA, Rocket App and Splashtop.
Award Winning Client Work and Global Recognition
Hotwire and individuals across the agency continue to gain recognition for leadership and impactful client work. Ludi Garcia, Managing Director of Hotwire Spain, was recently recognized as the #1 most admired communications professional in Spain by SCOPEN and Hotwire was named Best Comms PR consultancy, as voted for by PR professionals working in agencies.
Hotwire’s work on Zoomtopia, Zoom’s annual conference, received Honorable Mention for Ragan Comms' Media Relations Award for Virtual Event and is shortlisted in the PR report awards.
The company was also recently named in the Propel 100 list as one of the most influential PR agencies in the world in 2021.
Expanding Partnerships in The Tech Ecosystem
Hotwire is partnering with organizations across the world who are working to advance technology innovation and the leaders pushing the industry forward. The company is now a member of Tech UK , which brings together people, companies and organizations to realize the positive outcomes of what digital technology can achieve.
Hotwire is also a sponsor for Get On Board , which is a week of education and training to prepare women leaders for Board positions. The company is also a sponsor of Alley to the Valley , a community of accomplished women who fast-track business opportunities for each other. Hotwire supports board readiness and women in leadership with Executive Thought Leadership and Media Training and Speaker Readiness services.
To learn more about Hotwire, visit https://www.hotwireglobal.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005562/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
